Nektar Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
455 Mission Bay Blvd S, San Francisco, C...Phone Number
(415) 482-5300Website
www.nektar.comRevenue
$55.6 MillionStock Symbol
NKTRIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company focused on the research and development of innovative medicines designed to address serious unmet medical needs. The company is known for its expertise in advanced drug design and polymer conjugate technology, which it applies to enhance the effectiveness and safety of therapeutic compounds. Nektar Therapeutics concentrates on areas such as immunology, oncology, and autoimmune diseases, aiming to create treatments that modulate the immune system in precise and durable ways. Through a combination of in-house research and strategic collaborations, the company seeks to translate scientific insights into novel therapies that can improve patient outcomes.Explore more
Nektar Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nektar Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Nektar Therapeutics launches new products
Funding: Get notified immidiatlly once Nektar Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Nektar Therapeutics
Check out if Nektar Therapeutics is spiking on competitors!
Earning: See what the market has to say on Nektar Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Nektar Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Nektar Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Nektar Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Nektar Therapeutics
Find 2 more new buyers
Compare Similar Companies to Nektar Therapeutics
Compare insights from companies similar to Nektar Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Nektar Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nektar Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nektar Therapeutics.
Nektar Therapeutics financials insights
Gather financial insights about Nektar Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Debt
$125M
2013
Corporate Investment
$25M
2014
Stock Offering
$117M
2015
Debt
$250M
2016
Corporate Investment
$20M
Stock Offering
$175.5M
2018
Share Placement
$850M
2024
Share Placement
$30M
Nektar Therapeutics Tech Stack
A closer look at the technologies used by Nektar Therapeutics
See more technologies
Most Recent Scoops
Open Position
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Nektar Therapeutics News & Media
Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm
NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ: NKTR) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Nektar...Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive...Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, July 24, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on July 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 36,000 shares of its common...Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Two global registrational Phase 3 trials initiated in ZENITH AD program Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed in 393-patient Phase 2b study with monthly and quarterly maintenance dosing, including an up to five-fold increase in...
Read more news
Top Manufacturing Companies
Frequently Asked Questions Regarding Nektar Therapeutics
Sign Up For FreeTo access detailed company insights
Nektar Therapeutics is a biopharmaceutical company focused on the research and development of innovative medicines designed to address serious unmet medical needs. The company is known for its expertise in advanced drug design and polymer conjugate technology, which it applies to enhance the effectiveness and safety of therapeutic compounds. Nektar... Read More
